Boundless Bio announced that its Chief Executive Officer, Zachary Hornby, will present at the Oppenheimer 32nd Annual Healthcare Conference, which will take place virtually.
SAN DIEGO--(BUSINESS WIRE)-- Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Executive Officer, Zachary Hornby, will present at the Oppenheimer 32nd Annual Healthcare Conference, which will take place virtually. Presentation details are as follows:
Date: Tuesday, March 15, 2022
Time: 2:00 PM – 2:30 PM ET
About Boundless Bio
Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.
For more information, visit www.boundlessbio.com.
Follow us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220308005078/en/
James Lee
Director of Business Development
Boundless Bio
jlee@boundlessbio.com
Source: Boundless Bio
View this news release online at:
http://www.businesswire.com/news/home/20220308005078/en
